当前位置:药药网 / 药品研发 / 美国药品上市后承诺数据库
Nuwiq, Antihemophilic Factor (Recombinant), rAHF
申请企业
Octapharma Pharmazeutika Produktionsges.m.b.H.
药品名称
Nuwiq, Antihemophilic Factor (Recombinant), rAHF
承诺描述
GENA-99: Post-licensure trial to document long-term immunogenicity, safety, and efficacy of Antihemophilic Factor (Recombinant) in patients treated in normal clinical practice.
报告接收日期
2019/10/22 0:00:00